Literature DB >> 11641531

Is body mass index the prognostic factor in breast cancer?: a meta-analysis.

S Y Ryu1, C B Kim, C M Nam, J K Park, K S Kim, J Park, S Y Yoo, K S Cho.   

Abstract

This study was performed to integrate the results of previous studies that investigated the relationship between body mass index (BMI) and prognosis in breast cancer. We reviewed the English literatures using the MEDLINE database from 1966 to 1999. The materials included 12 published articles with a total of 8,029 cases of breast cancer. The effect size was obtained from hazard ratio in each study. Homogeneity test was conducted before the integration of each effect size and the result demonstrated that the studies were heterogeneous. A random effect model was used to integrate the overall effect size. The integrated effect size was 1.56 (95% confidence interval, 1.22-2.00). In addition, publication bias should be accounted for because each published study was asymmetric in shape revealed by funnel plot. These results suggest that BMI have a prognostic significance in breast cancer. We believe that well-designed longitudinal studies, involving a large number of samples are required to resolve these issues.

Entities:  

Mesh:

Year:  2001        PMID: 11641531      PMCID: PMC3057588          DOI: 10.3346/jkms.2001.16.5.610

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  14 in total

1.  Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project.

Authors:  Marilyn L Kwan; Wendy Y Chen; Candyce H Kroenke; Erin K Weltzien; Jeannette M Beasley; Sarah J Nechuta; Elizabeth M Poole; Wei Lu; Michelle D Holmes; Charles P Quesenberry; John P Pierce; Xiao Ou Shu; Bette J Caan
Journal:  Breast Cancer Res Treat       Date:  2011-12-21       Impact factor: 4.872

2.  Mammographic density as a predictor of breast cancer outcome.

Authors:  Gertraud Maskarinec; Christy G Woolcott; Laurence N Kolonel
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

3.  Plasma homocysteine and cysteine and risk of breast cancer in women.

Authors:  Jennifer Lin; I-Min Lee; Yiqing Song; Nancy R Cook; Jacob Selhub; JoAnn E Manson; Julie E Buring; Shumin M Zhang
Journal:  Cancer Res       Date:  2010-03-02       Impact factor: 12.701

4.  Obesity and risk of breast cancer mortality in Hispanic and Non-Hispanic white women: the New Mexico Women's Health Study.

Authors:  Avonne E Connor; Richard N Baumgartner; Christina Pinkston; Kathy B Baumgartner
Journal:  J Womens Health (Larchmt)       Date:  2013-03-26       Impact factor: 2.681

5.  Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors.

Authors:  Brandon L Pierce; Marian L Neuhouser; Mark H Wener; Leslie Bernstein; Richard N Baumgartner; Rachel Ballard-Barbash; Frank D Gilliland; Kathy B Baumgartner; Bess Sorensen; Anne McTiernan; Cornelia M Ulrich
Journal:  Breast Cancer Res Treat       Date:  2008-04-10       Impact factor: 4.872

6.  BMI influences prognosis following surgery and adjuvant chemotherapy for lymph node positive breast cancer.

Authors:  Mara Z Vitolins; Gretchen G Kimmick; L Douglas Case
Journal:  Breast J       Date:  2008 Jul-Aug       Impact factor: 2.431

7.  Aggressive estrogen-receptor-positive breast cancer arising in patients with elevated body mass index.

Authors:  Cesar Augusto Santa-Maria; Jingsheng Yan; Xian-Jin Xie; David Michael Euhus
Journal:  Int J Clin Oncol       Date:  2014-06-10       Impact factor: 3.402

8.  Cardiometabolic risk factors and survival after breast cancer in the Women's Health Initiative.

Authors:  Michael S Simon; Jennifer L Beebe-Dimmer; Theresa A Hastert; JoAnn E Manson; Elizabeth M Cespedes Feliciano; Marian L Neuhouser; Gloria Y F Ho; Jo L Freudenheim; Howard Strickler; Julie Ruterbusch; Ana Barac; Rowan Chlebowski; Bette Caan
Journal:  Cancer       Date:  2018-01-16       Impact factor: 6.860

9.  Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.

Authors:  Lynnette Fernández-Cuesta; Catherine Oakman; Priscila Falagan-Lotsch; Ke-Seay Smoth; Emmanuel Quinaux; Marc Buyse; M Stella Dolci; Evandro De Azambuja; Pierre Hainaut; Patrizia Dell'orto; Denis Larsimont; Prudence A Francis; John Crown; Martine Piccart-Gebhart; Giuseppe Viale; Angelo Di Leo; Magali Olivier
Journal:  Breast Cancer Res       Date:  2012-05-02       Impact factor: 6.466

10.  Body mass index is not associated with treatment outcomes of breast cancer patients receiving neoadjuvant chemotherapy: korean data.

Authors:  Kyung-Hun Lee; Bhumsuk Keam; Seock-Ah Im; Tae-Yong Kim; Sae-Won Han; Do-Youn Oh; Jee Hyun Kim; Se-Hoon Lee; Wonshik Han; Dong-Wan Kim; Tae-You Kim; In Ae Park; Dong-Young Noh; Dae Seog Heo; Yung-Jue Bang
Journal:  J Breast Cancer       Date:  2012-12-31       Impact factor: 3.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.